慢性HCV感染病毒清除后体外T细胞功能的动态变化
该研究对41例接受DAA治疗的慢性HCV感染者进行纵向分析,发现治疗第4周部分患者T细胞应答(主要为CD8+ T细胞)显著升高但随后减弱;治疗结束后12周体外HCV特异性CD8+ T细胞频率及抗原经验CD8+ T细胞群下降;DAA增加增殖能力但与体外功能无关;病毒突破或复发者T细胞功能恢复缺陷。结论:DAA介导的病毒清除仅短暂恢复体外T细胞功能。
要点
- DAA治疗第4周部分患者HCV特异性T细胞应答短暂升高,后期减弱。
- 治疗结束后12周体外HCV特异性CD8+ T细胞频率下降。
- 病毒突破或复发患者T细胞功能恢复存在缺陷。
核心结论
- DAA介导的病毒清除仅短暂恢复体外T细胞功能,提示需增强DAA治疗患者的T细胞功能。
研究设计与样本
- 纵向分析41例接受DAA治疗的慢性HCV感染患者,检测体外HCV特异性CD8+ T细胞功能与表型变化。
主要发现
- 部分患者治疗第4周T细胞应答(主要为CD8+ T细胞)显著升高,但 later weeks 减弱。
- 与治疗前相比,治疗结束后12周体外HCV特异性CD8+ T细胞频率下降,抗原经验CD8+ T细胞群减少。
- DAA治疗增加HCV特异性CD8+ T细胞增殖能力,但该变化与体外功能不相关。
- 发生病毒突破或复发的患者T细胞功能恢复缺陷。
临床怎么用
- DAA治疗清除HCV后体外T细胞功能恢复短暂,临床需关注免疫恢复策略。
- 对病毒突破或复发患者应评估T细胞功能恢复情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct-acting antiviral (DAA) agents can successfully treat chronic hepatitis C virus (HCV) infection. However, the ex vivo HCV-specific T-cell function following viral clearance remains unknown. METHODS: We investigated functional alterations and phenotypic changes in ex vivo HCV-specific CD8+ T cells with a longitudinal analysis of 41 patients with chronic HCV infection who were undergoing DAA treatment. RESULTS: A patient subset exhibited a significantly increased T-cell response (mainly CD8+ T cells) at week 4 of treatment. However, this increased T-cell response diminished in later weeks. Relative to pretreatment levels, the ex vivo HCV-specific CD8+ T-cell frequency decreased at 12 weeks after the end of treatment, along with a decreased antigen-experienced CD8+ T-cell population. DAA treatment increased the proliferative capacity of HCV-specific CD8+ T cells, but this change was not correlated with ex vivo function. Patients experiencing viral breakthrough or relapse exhibited defective restoration of T-cell function. CONCLUSION: Our present results indicated that DAA-mediated viral clearance only transiently restored ex vivo T-cell function, suggesting a need to enhance T-cell function in DAA-treated patients.
引用
- Han JW, Sung PS, Kim KH, et al. Dynamic Changes in Ex Vivo T-Cell Function After Viral Clearance in Chronic HCV Infection. J Infect Dis. 2019. PMID: 31152667. doi:10.1093/infdis/jiz291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。